Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 3/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | GIPR | P48546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1481857 | 1.00 | DRD2 (0.44) | DRD2POLBMAPTHDAC1HDAC6 | |
| SCHEMBL1481757 | 0.93 | DRD2 (0.45) | DRD2POLBMAPTGCGRNLRP3 | |
| SCHEMBL1481756 | 0.93 | DRD2 (0.45) | DRD2POLBMAPTGCGRNLRP3 | |
| SCHEMBL1676687 | 0.93 | DRD2 (0.41) | DRD2POLBMAPTSERPINE1GCGR | |
| SCHEMBL1676690 | 0.93 | DRD2 (0.41) | DRD2POLBMAPTSERPINE1GCGR | |
| SCHEMBL1481366 | 0.93 | SERPINE1 (0.41) | HDAC1HDAC6SERPINE1GCGRGIPR | |
| SCHEMBL1481369 | 0.93 | SERPINE1 (0.41) | HDAC1HDAC6SERPINE1GCGRGIPR | |
| SCHEMBL1481344 | 0.91 | DRD2 (0.44) | DRD2POLBMAPTHDAC1HDAC6 | |
| SCHEMBL1481346 | 0.91 | DRD2 (0.44) | DRD2POLBMAPTHDAC1HDAC6 | |
| SCHEMBL1482394 | 0.90 | DRD2 (0.48) | DRD2POLBMAPTPLAUNLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | DRD2 4864/4885POLB 4328/4885MAPT 3558/4885 |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | PTPRO, PTPN5, PTPRE | DRD2 4873/4885POLB 4497/4885MAPT 3251/4885 |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | PTPRS, PTPRO, PTPRJ | DRD2 4864/4885POLB 4328/4885MAPT 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.